IFNA1 and Bruton-type agammaglobulinemia: Therefore, based on our findings and previous reports, we postulated the increased risk of VAPP in XLA patients is due to combined deficiency of IFN and antibody which impairs defenses at various checkpoints against the development of VAPP after OPV vaccination (Figure 8).